Is blockade of vascular endothelial growth factor beneficial for all types of diabetic retinopathy?
Sang
D N
DN
Schepens Eye Research Institute, 20 Staniford Street, Boston, MA 02114, USA.
D'Amore
P A
PA
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D003930:Diabetic Retinopathy / Q000517:prevention & control*; D006801:Humans; D008268:Macular Degeneration / Q000517:prevention & control; D000069579:Ranibizumab; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000069579:Ranibizumab